[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484902":3},{"organization":4,"armGroups":7,"interventions":133,"overallOfficials":138,"centralContacts":213,"locations":220,"responsibleParty":250,"collaborators":253,"id":284,"slug":285,"hasResults":286,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":138,"eligibilityCriteria":290,"healthyVolunteers":286,"sex":291,"minAge":292,"maxAge":138,"enrollmentInfo":293,"targetDuration":138,"studyType":296,"phases":297,"briefSummary":299,"conditions":300,"keywords":138,"overallStatus":223,"whyStopped":138,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},{"fullName":5,"class":6},"Fudan University","OTHER",[8,16,21,26,33,39,44,49,53,58,62,66,71,76,81,86,90,96,100,104,108,112,117,121,125,129],{"label":9,"type":10,"description":11,"interventionNames":12},"SNF1 1A: PIK3CA mutation","EXPERIMENTAL","PIK3CA inhibitors +Aromatase inhibitors(Letrozole\u002FAnastrozole\u002FExemestane, po, qd, specific dose (letrozole 2.5mg\u002F day; Anastrozole 1mg\u002F day, Exemestane 25mg\u002F day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.",[13,14,15],"Drug: PIK3CA inhibitor","Drug: Aromatase Inhibitors or Fulvestrant","Drug: Goserelin",{"label":17,"type":10,"description":18,"interventionNames":19},"SNF1 1B: AKT pathway mutation","AKT pathway inhibitors +Aromatase inhibitors(Letrozole\u002FAnastrozole\u002FExemestane, po, qd, specific dose (letrozole 2.5mg\u002F day; Anastrozole 1mg\u002F day, Exemestane 25mg\u002F day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.",[20,14,15],"Drug: AKT inhibitor",{"label":22,"type":10,"description":23,"interventionNames":24},"SNF1 1C: without above mutation","Everolimus 10mg po qd+Aromatase inhibitors(Letrozole\u002FAnastrozole\u002FExemestane, po, qd, specific dose (letrozole 2.5mg\u002F day; Anastrozole 1mg\u002F day, Exemestane 25mg\u002F day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.",[25,14,15],"Drug: Everolimus",{"label":27,"type":10,"description":28,"interventionNames":29},"SNF2 2A","Treatment of physician' choice+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib 15mg po qd for 4 weeks as a cycle",[30,31,32],"Drug: Carrelizumab","Drug: Famitinib","Drug: TPC",{"label":34,"type":10,"description":35,"interventionNames":36},"SNF3 3A: Stratification of BRCA\u002FPALB2 expression","Fluzoparib SHR3162 100mg po qd+Dalpiciclib 125mg po qd for 4 weeks as a cycle",[37,38],"Drug: Fluzoparib","Drug: Dalpiciclib",{"label":40,"type":10,"description":41,"interventionNames":42},"SNF4 4A: HER2 low","SHR-A1811",[43],"Drug: SHR-A1811",{"label":45,"type":46,"description":47,"interventionNames":48},"The control arm","ACTIVE_COMPARATOR","Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)",[32],{"label":50,"type":10,"description":51,"interventionNames":52},"SNF3 3B:","Fluzoparib SHR3162 100 mg qd+Treatment of physician' choice",[37,32],{"label":54,"type":10,"description":55,"interventionNames":56},"SNF4 4B:","Apatinib 250mg qd+Treatment of physician' choice",[32,57],"Drug: Apatinib",{"label":59,"type":10,"description":60,"interventionNames":61},"SNF1 1D: without above mutation","Everolimus 10mg po qd+Treatment of physician' choice",[25,32],{"label":63,"type":10,"description":64,"interventionNames":65},"SNF1 1E: HER2 LOW","Everolimus 10mg po qd+SHR-A1811",[43,25],{"label":67,"type":10,"description":68,"interventionNames":69},"SNF1 1F: HER2 zero","Everolimus 10mg po qd+SHR-A1921",[25,70],"Drug: SHR-A1921",{"label":72,"type":10,"description":73,"interventionNames":74},"SNF2 2B: HER2 zero","SHR-A1921+Pd-1 mab (Carrelizumab 200mg Q2W)+bevacizumab 7.5mg po ivgt t for 3 weeks as a cycle",[30,70,75],"Drug: bevacizumab",{"label":77,"type":10,"description":78,"interventionNames":79},"SNF2 2C:","HER3 -ADC+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib for 3 weeks as a cycle",[30,31,80],"Drug: SHR-A2009",{"label":82,"type":10,"description":83,"interventionNames":84},"SNF2 2D:","Nectin4-ADC+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib for 3 weeks as a cycle",[30,31,85],"Drug: SHR-A2102",{"label":87,"type":10,"description":88,"interventionNames":89},"SNF2 2E: HER2 low","SHR-A1811+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib for 3 weeks as a cycle",[30,31,43],{"label":91,"type":10,"description":92,"interventionNames":93},"SNF3 3C:","CDK4i（SHR-6209 PR2D+PARP1i（SHR-1167 PR2D）",[94,95],"Drug: SHR-1167","Drug: SHR-6209",{"label":97,"type":10,"description":98,"interventionNames":99},"SNF3 3D:","PARP1i（SHR-1167 PR2D)+Famitinib 5mg po qd for 4 weeks as a cycle",[31,94],{"label":101,"type":10,"description":102,"interventionNames":103},"SNF3 3E: HER2 low","PARP1i（SHR-1167 PR2D)+SHR-A1811 for 3 weeks as a cycle",[43,94],{"label":105,"type":10,"description":106,"interventionNames":107},"SNF3 3F: HER2 zero","PARP1i（SHR-1167 PR2D)+SHR-A1921 for 3 weeks as a cycle",[70,94],{"label":109,"type":10,"description":110,"interventionNames":111},"SNF4 4C","Famitinib 20mg po qd",[31],{"label":113,"type":10,"description":114,"interventionNames":115},"SNF4 4D","Sorafenib 0.4g bid",[116],"Drug: Sorafenib",{"label":118,"type":10,"description":119,"interventionNames":120},"SNF4 4E","Apatinib 500mg qd",[57],{"label":122,"type":10,"description":123,"interventionNames":124},"SNF4 4F: HER2 low","Famitinib+SHR-A1811 for 3 weeks as a cycle",[31,43],{"label":126,"type":10,"description":127,"interventionNames":128},"SNF4 4G","Famitinib+HER3-ADC for 3 weeks as a cycle",[31,80],{"label":130,"type":10,"description":131,"interventionNames":132},"SNF4 4H","Famitinib+Nectin4-ADC for 3 weeks as a cycle",[31,85],[134,139,142,148,152,158,164,167,171,175,179,182,186,190,194,198,202,206,210],{"type":135,"name":136,"description":136,"armGroupLabels":137,"otherNames":138},"DRUG","PIK3CA inhibitor",[9],null,{"type":135,"name":140,"description":140,"armGroupLabels":141,"otherNames":138},"AKT inhibitor",[17],{"type":135,"name":143,"description":144,"armGroupLabels":145,"otherNames":146},"Carrelizumab","Pd-1 mab",[27,72,77,82,87],[147],"SHR1210",{"type":135,"name":149,"description":150,"armGroupLabels":151,"otherNames":138},"Famitinib","VEGFR inhibitor",[27,77,82,87,97,109,122,126,130],{"type":135,"name":153,"description":154,"armGroupLabels":155,"otherNames":156},"Fluzoparib","PARP inhibitor",[34,50],[157],"SHR3162",{"type":135,"name":159,"description":160,"armGroupLabels":161,"otherNames":162},"Dalpiciclib","CDK4\u002F6 inhibitor",[34],[163],"SHR6390",{"type":135,"name":41,"description":165,"armGroupLabels":166,"otherNames":138},"HER2 ADC",[63,87,101,40,122],{"type":135,"name":168,"description":169,"armGroupLabels":170,"otherNames":138},"Everolimus","mTOR inhibior",[22,59,63,67],{"type":135,"name":172,"description":173,"armGroupLabels":174,"otherNames":138},"Aromatase Inhibitors or Fulvestrant","Letrozole\u002FAnastrozole\u002FExemestane or Fulvestrant",[9,17,22],{"type":135,"name":176,"description":177,"armGroupLabels":178,"otherNames":138},"Goserelin","For premenopause",[9,17,22],{"type":135,"name":180,"description":47,"armGroupLabels":181,"otherNames":138},"TPC",[59,27,50,54,45],{"type":135,"name":183,"description":184,"armGroupLabels":185,"otherNames":138},"Sorafenib","RTK Inhibitor",[113],{"type":135,"name":187,"description":188,"armGroupLabels":189,"otherNames":138},"Apatinib","Apatinib 250mg po qd",[54,118],{"type":135,"name":191,"description":192,"armGroupLabels":193,"otherNames":138},"SHR-A1921","TROP2 ADC",[67,72,105],{"type":135,"name":195,"description":196,"armGroupLabels":197,"otherNames":138},"SHR-A2102","NECTIN4 ADC",[82,130],{"type":135,"name":199,"description":200,"armGroupLabels":201,"otherNames":138},"SHR-A2009","HER3 ADC",[77,126],{"type":135,"name":203,"description":204,"armGroupLabels":205,"otherNames":138},"SHR-1167","PARP1i",[91,97,101,105],{"type":135,"name":207,"description":208,"armGroupLabels":209,"otherNames":138},"SHR-6209","CDK4i",[91],{"type":135,"name":211,"description":211,"armGroupLabels":212,"otherNames":138},"bevacizumab",[72],[214],{"name":215,"role":216,"phone":217,"phoneExt":218,"email":219},"Zhimin Shao, M.D","CONTACT","+86-021-64175590","88807","zhimingshao@yahoo.com",[221],{"facility":222,"status":223,"city":224,"state":225,"zip":226,"country":227,"countryCode":228,"cosmosGeoPoint":229,"geoPoint":234,"contacts":235},"Breast cancer institute of Fudan University Cancer Hospital","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":230,"coordinates":231},"Point",[232,233],121.45806,31.22222,{"lat":233,"lon":232},[236,239,242,244,246,248],{"name":237,"role":216,"phone":238,"phoneExt":138,"email":219},"Zhi-Ming Shao, MD","86-21-641755901105",{"name":240,"role":216,"phone":238,"phoneExt":138,"email":241},"Lei Fan, MD","cmchen@medmail.com.cn",{"name":237,"role":243,"phone":138,"phoneExt":138,"email":138},"PRINCIPAL_INVESTIGATOR",{"name":240,"role":245,"phone":138,"phoneExt":138,"email":138},"SUB_INVESTIGATOR",{"name":247,"role":245,"phone":138,"phoneExt":138,"email":138},"Wenjuan Zhang, MD",{"name":249,"role":245,"phone":138,"phoneExt":138,"email":138},"Ying Zhou",{"type":243,"investigatorFullName":251,"investigatorTitle":252,"investigatorAffiliation":5,"oldNameTitle":138,"oldOrganization":138},"Zhimin Shao","Professor",[254,256,258,260,262,264,266,268,271,273,275,277,280,282],{"name":255,"class":6},"Peking University Cancer Hospital & Institute",{"name":257,"class":6},"First Hospital of China Medical University",{"name":259,"class":6},"Sun Yat-sen University",{"name":261,"class":6},"First Affiliated Hospital Xi'an Jiaotong University",{"name":263,"class":6},"Chongqing University Cancer Hospital",{"name":265,"class":6},"Northern Jiangsu People's Hospital",{"name":267,"class":6},"Fujian Medical University Union Hospital",{"name":269,"class":270},"Ningbo Medical Center Lihuili Hospital","OTHER_GOV",{"name":272,"class":6},"Shanghai First Maternity and Infant Hospital",{"name":274,"class":6},"Shanghai 6th People's Hospital",{"name":276,"class":6},"Affiliated Hospital of Nantong University",{"name":278,"class":279},"Nanchang People's Hospital","UNKNOWN",{"name":281,"class":6},"Liaoning Cancer Hospital & Institute",{"name":283,"class":6},"The First Hospital of Jilin University","100484902","phase-2-snf-platform-study-of-hr-her2-advanced-breast-cancer-100484902",false,"NCT05594095","SNF Platform Study of HR+\u002F HER2-advanced Breast Cancer","Precision Platform Study of HR+\u002F HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)","Inclusion Criteria:\n\n1. Female aged ≥18 years;\n2. HR+\u002FHER2- invasive breast cancer confirmed by histology (specific definition: ER \\>10% positive tumor cells by immunohistochemistry is defined as ER positive, PR \\>10% positive tumor cells is defined as PR positive, ER and\u002For PR positive is defined as HR positive; HER2 0-1+ or HER2 + but negative by FISH without amplification was defined as HER2 negative);\n3. Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent metastatic breast cancer;\n4. HR+\u002FHER2- advanced breast cancer patients who had previously received CDK4\u002F6 inhibitor therapy;\n5. At least one measurable lesion according to RECIST 1.1 (conventional CT scan ≥20 mm, spiral CT scan ≥10 mm, measurable lesion has not received radiotherapy);\n6. The functions of the main organs are basically normal and meet the following conditions:\n\n   I. Blood routine examination criteria shall meet: HB ≥90 g\u002FL (no blood transfusion within 14 days); The ANC acuity 1.5 x 109 \u002F L; PLT acuity 75 x 109 \u002F L; Ii. Biochemical tests should meet the following criteria: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN; Serum Cr ≤1×ULN, endogenous creatinine clearance \\> 50 ml\u002Fmin (Cockcroft-Gault formula);\n7. They have not received radiotherapy, molecular targeted therapy, or surgery within 3 weeks before the start of the study, and have recovered from the acute toxicity of previous treatment (if surgery was performed, the wound has healed completely); No peripheral neuropathy or grade I peripheral neurotoxicity;\n8. ECOG score ≤2, and life expectancy ≥3 months;\n9. Fertile female subjects were required to use a medically approved contraceptive method during the study treatment period and for at least 3 months after the last use of the study drug;\n10. Subjects volunteered to join the study, signed informed consent, had good compliance, and cooperated with follow-up.\n\nExclusion Criteria:\n\n1. Radiotherapy (except for palliative causes), chemotherapy, and immunotherapy were used in the first 3 weeks of treatment, except bisphosphonate (which can be used for bone metastasis);\n2. Uncontrolled central nervous system metastases (indicating symptomatic or symptomatic treatment with glucocorticoids or mannitol);\n3. A history of clinically important or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia within the last 6 months;\n4. Persistent grade 1 or higher adverse reactions caused by previous treatments. The exception to this is hair loss or something the researchers don't think should be ruled out. Such cases should be clearly documented in the investigator's notes;\n5. Underwent major surgery (except minor outpatient procedures, such as placement of vascular access) within 3 weeks of the first course of trial treatment;\n6. Pregnant or lactating patients; Malignancy (except basal cell carcinoma of the skin, which has been cured, and carcinoma in situ of the cervix) in the past 5 years.","FEMALE","18 Years",{"count":294,"type":295},620,"ESTIMATED","INTERVENTIONAL",[298],"PHASE2","The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4\u002F6 inhibitors.",[301,302,303,304,305],"Breast Neoplasm","Breast Cancer","Hormone Receptor Positive Tumor","HER2-negative Breast Cancer","Advanced Breast Cancer","2024-10-02",{"date":308,"type":309},"2024-10-04","ACTUAL",{"date":311,"type":309},"2022-12-30",{"date":313,"type":295},"2026-12-01",{"name":5,"class":6},1]